SEC For	m 4																	
	FORM	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB APPROVAL			
Section obligat	this box if no k n 16. Form 4 or ions may conti tion 1(b).	STATEMENT OF CHANGES IN BENEFICIAL OWNERS Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940												OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
<u>Yan Mi</u> (Last)	nd Address of ing (F FEK BIOS((Middle)	2. Issuer Name and Ticke <u>Cytek Bioscience</u> 3. Date of Earliest Transa 03/06/2024				es, Inc. [CTKB]				(Ch	5. Relationship of Reporting Person(s) to Issuer Check all applicable) X Director 10% Owner X Officer (give title Other (specif below) CHIEF TECHNOLOGY OFFICER				wner specify		
47215 L	AKEVIEW	94538		4.	Line) X Form filed by On								roup Filing (Check Applicable One Reporting Person More than One Reporting					
(City) (State) (Zip) Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intervent the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												t is intended	to satisfy					
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Trans Date (Month/I)				actio	action 2A. Deemed Execution Date			ar) 3. Transact Code (In 8)	tion str.	str.			5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Table II - I	Derivat (e.g., p	tive uts	e Sec , cal	urities Is, warr	Aco		spc s, c	sed of,	or Ben ble sec	eficially urities)	(Instr. 3 a	ind 4)			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/)	Co	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Beneficia Owned Followin Reported	re es ally g d	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				co	ode	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares]	Transact (Instr. 4)			
Employee Stock Option (right to buy)	\$7.07	03/06/2024		1	A		131,578		(1)	0.	3/06/2034	Common Stock	131,578	\$0	131,578		D	
Restricted							1			╈		C	1	1	İ 👘			1

Explanation of Responses:

(2)

Stock Units

1. The shares subject to the option shall vest over 4 years with 1/48 of the total shares underlying the option vesting on April 6, 2024 and each month thereafter.

88,401

Α

2. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

3. The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each May 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter.

(3)

/s/ Valerie Barnett, Attorney-in-03/08/2024 Fact

\$<mark>0</mark>

88,401

D

** Signature of Reporting Person Date

88,401

Common Stock

(3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

03/06/2024

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.